Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
Status:
Terminated
Trial end date:
2020-07-21
Target enrollment:
Participant gender:
Summary
The trial evaluates the efficacy and safety of Tocilizumab, which rapidly reduces the
inflammation process through inhibition of IL-6 in patients with moderate to severe COVID-19
with increased inflammatory markers. There will be two arms in the trial, one receiving the
best supportive care, and the other receiving it plus tocilizumab. Patients will be followed
until Day 29 after randomization.
Phase:
Phase 3
Details
Lead Sponsor:
Beneficência Portuguesa de São Paulo
Collaborators:
Brazilian Clinical Research Institute Brazilian Research In Intensive Care Network Federal University of São Paulo Hospital Alemão Oswaldo Cruz Hospital do Coracao Hospital Israelita Albert Einstein Hospital Moinhos de Vento Hospital Sirio-Libanes